Skip to main content

Advertisement

SpringerLink
Log in

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Zoledronic acid treatment reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer. The aim of this study was to evaluate the effect of zoledronic acid on SREs in patients with bone metastases from bladder cancer.

Patients and methods

Patients with bone metastases from bladder cancer who were receiving palliative radiotherapy were randomized to placebo or zoledronic acid (4 mg intravenous monthly) for 6 months.

Results

The patients (n = 40) were evenly distributed between the two treatment groups, and the baseline demographics of the two groups were similar. The follow-up varied from 8 to 65 weeks (median 24 weeks). Compared with patients receiving placebo, those receiving zoledronic acid had a lower mean incidence of SREs (2.05 ± 1.0 vs. 0.95 ± 0.9, respectively), and a larger proportion did not experience an on-study SRE (2 vs. 8 patients, respectively). Zoledronic acid also prolonged the median time to first SRE compared with the placebo (16 vs. 8 weeks, respectively). Multiple event analysis of SREs revealed that zoledronic acid decreased the risk of SRE development by 59% (hazard ratio 0.413). Zoledronic acid also increased the 1-year survival rate compared with placebo (36.3 ± 11.2 vs. 0%, respectively). Zoledronic acid was generally well tolerated in our patient population.

Conclusions

Zoledronic acid therapy decreased the incidence of SREs and improved the 1-year survival rate of patients with bone metastases from bladder cancer, potentially through its anticancer activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218:12–20

    Google Scholar 

  3. Zaghloul MS (2006) Adjuvant radiation therapy for locally advanced bladder cancer. In: US Oncological Disease. Touch Briefings, London, pp 86–89

  4. Miller LS (1977) Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39:973–980

    Article  CAS  PubMed  Google Scholar 

  5. Zaghloul MS (1996) Distant metastasis from bilharzial bladder cancer. Cancer 77:743–749

    Article  CAS  PubMed  Google Scholar 

  6. Volkmer BG, Kuefer R, Bartsch GC Jr et al (2009) Oncological followup after radical cystectomy for bladder cancer—is there any benefit? J Urol 181:1587–1593 (discussion 1593)

    Article  PubMed  Google Scholar 

  7. Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621

    Article  CAS  PubMed  Google Scholar 

  8. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157

    Article  CAS  PubMed  Google Scholar 

  9. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744

    Article  CAS  PubMed  Google Scholar 

  10. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    Article  CAS  PubMed  Google Scholar 

  11. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 23:129–138

    CAS  PubMed  Google Scholar 

  12. Cook RJ, Lawless JF (2002) Analysis of repeated events. Stat Methods Med Res 11:141–166

    Article  CAS  PubMed  Google Scholar 

  13. Lipton A (2007) Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 4:92–100

    Article  CAS  PubMed  Google Scholar 

  14. Saad F (2008) New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 34:183–192

    Article  CAS  PubMed  Google Scholar 

  15. Saad F, Lipton A (2007) Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 34:S17–S23

    Article  CAS  PubMed  Google Scholar 

  16. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176

    Article  CAS  PubMed  Google Scholar 

  17. Weinfurt KP, Anstrom KJ, Castel LD et al (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986–989

    Article  CAS  PubMed  Google Scholar 

  18. Mystakidou K, Katsouda E, Parpa E et al (2005) Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22:195–201

    Article  CAS  PubMed  Google Scholar 

  19. Aviles A, Nambo MJ, Neri N et al (2007) Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24:227–230

    Article  CAS  PubMed  Google Scholar 

  20. Zarogoulidis K, Boutsikou E, Zarogoulidis P et al (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125:1705–1709

    Article  CAS  PubMed  Google Scholar 

  21. Guise TA (2008) Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 34[Suppl 1]:S19–S24

    Article  CAS  PubMed  Google Scholar 

  22. Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453–475

    Article  CAS  PubMed  Google Scholar 

  23. Wood J, Bonjean K, Ruetz S et al (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061

    Article  CAS  PubMed  Google Scholar 

  24. Tas F, Duranyildiz D, Oguz H et al (2008) Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol 25:346–349

    Article  CAS  PubMed  Google Scholar 

  25. Kunzmann V, Bauer E, Feurle J et al (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392

    CAS  PubMed  Google Scholar 

  26. Santini D, Martini F, Fratto ME et al (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31–38

    Article  CAS  PubMed  Google Scholar 

  27. Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691

    Article  CAS  PubMed  Google Scholar 

  28. Brufsky A, Bundred N, Coleman R et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503–514

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Rosemary E. Teresi, PhD, ProEd Communications, for her medical editorial assistance with this manuscript.

Conflict of interest statement

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt

    Mohamed S. Zaghloul, Rimoun Boutrus, Hisham El-Hossieny, Yasser Abdel Kader & Mohamed Nazmy

  2. Medical Statistics Department, National Cancer Institute, Cairo University, Cairo, Egypt

    Inas El-Attar

  3. Radiation Oncology Department, Children’s Cancer Hospital (CCHE) 57357, 1 Sekket El Emam, Sayeda Zainab, Cairo, Egypt

    Mohamed S. Zaghloul

Authors
  1. Mohamed S. Zaghloul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rimoun Boutrus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hisham El-Hossieny
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasser Abdel Kader
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inas El-Attar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohamed Nazmy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed S. Zaghloul.

About this article

Cite this article

Zaghloul, M.S., Boutrus, R., El-Hossieny, H. et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15, 382–389 (2010). https://doi.org/10.1007/s10147-010-0074-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-010-0074-5

Keywords

Search

Navigation